Phase II trial of oral gimatecan in adults with recurrent glioblastoma

被引：0
|
作者：
Hu, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Wen, P. Y. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Abrey, L. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Fadul, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Drappatz, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Salem, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Amato, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Carminati, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Supko, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Hochberg, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Massachusetts Gen Hosp, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02114 USA
[2] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[5] Sigma Tau Res Inc, Gaithersburg, MD USA
[6] Sigma Tau Ind Farmaceut Reiunite SpA, Pomezia, Italy
[7] Harvard Univ, Ctr Canc, Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2009
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
    Lassman, Andrew B.
    Wen, Patrick Y.
    van den Bent, Martin J.
    Plotkin, Scott R.
    Walenkamp, Annemiek M. E.
    Green, Adam L.
    Li, Kai
    Walker, Christopher J.
    Chang, Hua
    Tamir, Sharon
    Henegar, Leah
    Shen, Yao
    Alvarez, Mariano J.
    Califano, Andrea
    Landesman, Yosef
    Kauffman, Michael G.
    Shacham, Sharon
    Mau-Sorensen, Morten
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 452 - 460
  • [22] Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
    Badruddoja, Michael A.
    Penne, Kara
    Desjardins, Annick
    Reardon, David A.
    Rich, Jeremy N.
    Quinn, Jennifer A.
    Sathornsumetee, Sith
    Friedman, Allan H.
    Bigner, Darell D.
    Herndon, James E., II
    Cahill, Ann
    Friedman, Henry S.
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2007, 9 (01) : 70 - 74
  • [23] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [24] Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
    Reynes, Gaspar
    Martinez-Sales, Vicenta
    Vila, Virtudes
    Balana, Carmen
    Perez-Segura, Pedro
    Vaz, Maria A.
    Benavides, Manuel
    Gallego, Oscar
    Palomero, Isabel
    Gil-Gil, Miguel
    Fleitas, Tania
    Reche, Encarnacion
    ANTI-CANCER DRUGS, 2016, 27 (02) : 133 - 137
  • [25] FEASIBILITY AND PHASE I/II TRIAL OF TANDUTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Batchelor, Tracy
    Grossman, Stuart
    Brem, Steve
    Lesser, Glenn
    Voloschin, Alfredo
    Nabors, Louis B.
    Mikkelsen, Tom
    Desideri, Serena
    Supko, Jeffrey
    Peereboom, David
    NEURO-ONCOLOGY, 2011, 13 : 89 - 89
  • [26] PRELIMINARY RESULTS OF A PHASE 1 TRIAL OF ORAL GALLIUM MALTOLATE IN RECURRENT GLIOBLASTOMA
    Connelly, Jennifer
    Zoss, Casey
    Schmainda, Kathleen
    Al-Gizawiy, Mona
    Pinheiro, Fernando Santos
    Chitambar, Christopher
    NEURO-ONCOLOGY, 2023, 25
  • [27] A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM)
    Phuphanich, S.
    Rudnick, J.
    Chu, R.
    Yu, J. S.
    Black, K. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
    Kalpathy-Cramer, Jayashree
    Chandra, Vyshak
    Da, Xiao
    Ou, Yangming
    Emblem, Kyrre E.
    Muzikansky, Alona
    Cai, Xuezhu
    Douw, Linda
    Evans, John G.
    Dietrich, Jorg
    Chi, Andrew S.
    Wen, Patrick Y.
    Stufflebeam, Stephen
    Rosen, Bruce
    Duda, Dan G.
    Jain, Rakesh K.
    Batchelor, Tracy T.
    Gerstner, Elizabeth R.
    JOURNAL OF NEURO-ONCOLOGY, 2017, 131 (03) : 603 - 610
  • [29] Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
    Jayashree Kalpathy-Cramer
    Vyshak Chandra
    Xiao Da
    Yangming Ou
    Kyrre E. Emblem
    Alona Muzikansky
    Xuezhu Cai
    Linda Douw
    John G. Evans
    Jorg Dietrich
    Andrew S. Chi
    Patrick Y. Wen
    Stephen Stufflebeam
    Bruce Rosen
    Dan G. Duda
    Rakesh K. Jain
    Tracy T. Batchelor
    Elizabeth R. Gerstner
    Journal of Neuro-Oncology, 2017, 131 : 603 - 610
  • [30] PHASE II TRIAL OF NILOTINIB IN PDGFR-ALPHA ENRICHED RECURRENT GLIOBLASTOMA
    Picconi, David
    Juarez, Tiffany
    Kesari, Santosh
    NEURO-ONCOLOGY, 2019, 21 : 26 - 26
12345